Pharmaceutical Technology

APRIL 20, 2023

Biopharmaceutical company Abdera Therapeutics has raised $142m in combined Series A and B financing to engineer and advance antibody-based radiopharmaceuticals to treat cancer. The company’s lead programme is aimed at delta-like ligand 3 (DLL3), which is a protein in the Notch pathway.

Antibody 130

Antibody Engineer Protein Drugs 130

Scienmag

FEBRUARY 7, 2022

The SARS-CoV-2 nucleoprotein is the main protein in viral particles. COVID-19 patients usually develop antibodies (immunity proteins that are specifically […]. It folds the RNA of the virus into a compact structure.

Antibody 82

Antibody RNA Protein Development 82

The Pharma Data

APRIL 15, 2022

A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Designed computationally and refined in the laboratory, the new protein therapies thwarted infection by interfering with the virus’ ability to enter cells. Diamond at WashU.

Antibody 52

Antibody Protein Engineer Research 52

XTalks

MARCH 31, 2023

By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability. The proteins will be analyzed back on Earth using techniques such as X-ray diffraction and compared with crystals from the same biologics grown on Earth.

Protein 78

Protein Research Development Manufacturing 78

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. At the helm of this venture is Dr. Taylor H. How is your lead program differentiated?

Protein 68

Protein Development Clinical Trials Clinical Trials 68

Pharmaceutical Technology

APRIL 13, 2023

Clinical-stage biopharmaceutical firm Alentis Therapeutics has raised $105m in a Series C financing round for advancing transformational medicines targeting the CLAUDIN-1 protein. ALE.F02 is being developed for the treatment of advanced kidney, lung and liver fibrosis while ALE.C04 is a potential treatment to target CLDN1-positive tumours.

Medicine 130

Medicine Development Antibody Engineer 130

Medical Xpress

FEBRUARY 7, 2023

Patients usually receive FVIII that comes from donor blood or is produced using genetic engineering. However, about one third of those treated for severe hemophilia A develop antibodies (inhibitors) against FVIII.

Antibody 40

Antibody Genetic Engineering Development Engineer 40

BioPharma Reporter

MAY 16, 2023

LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting.

Engineer 52

Engineer Protein Antibody 52

Scienmag

JANUARY 6, 2021

today announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer. This collaboration joins Xencor’s innovative XmAb® technology and protein engineering expertise to create bispecific antibodies […].

Antibody 45

Antibody Development Engineer Protein 45

The Pharma Data

AUGUST 15, 2021

Now, researchers reporting in ACS Central Science have immunized mice with nanoparticles that mimic SARS-CoV-2 by displaying multiple copies of the receptor binding domain (RBD) antigen, showing that the vaccine triggers robust antibody and T cell responses. Although the first vaccines to receive Emergency Use Authorization by the U.S.

Protein 52

Protein Vaccination Vaccine Antibody 52

pharmaphorum

MAY 12, 2021

UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in on the action. . The post Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn deal appeared first on.

RNA 76

RNA Protein Drugs Pharma Companies 76

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 1.351 variant.

Protein 77

Protein Vaccination Vaccine Trials 77

The Pharma Data

NOVEMBER 22, 2020

FJB) and IONTAS Limited (IONTAS), leaders in the discovery and optimization of VHH and fully human antibodies, today announced they have signed an agreement to discover antibodies with Pandion Therapeutics (Pandion). PORTO, Portugal & CAMBRIDGE, England & LONDON–( BUSINESS WIRE )– FairJourney Biologics S.A (FJB)

Antibody 52

Antibody Engineer Immune Response Protein 52

Pharmaceutical Technology

MARCH 14, 2023

It is a pioneer in antibody-drug conjugates (ADCs) technology. The deal will also use the protein engineering and medicinal chemistry capabilities of Pfizer to advance Seagen’s ADC technology to unlock next-generation biologics and potential new target combinations.

Antibody 130

Antibody Medicine Engineer Protein 130

Pharmaceutical Technology

NOVEMBER 29, 2022

For this approach, the team leveraged an oncolytic herpes simplex virus for releasing chemokines, which are signalling proteins that aid in attracting immune cells to tumours. These viruses are engineered genetically for killing cancer. The antibody is produced by the tumour cells infected by the oncolytic virus.

Development 130

Development Research Antibody Engineer 130

pharmaphorum

NOVEMBER 2, 2021

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Though their bispecific nature complicates large-scale production and purification workflows, with challenges such as antibody chain mispairing, bsAbs have come a long way since first developed.

Antibody 52

Antibody Immune Response Production Engineer 52

The Pharma Data

APRIL 12, 2023

Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement Biogen Inc. Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ).

Antibody 40

Antibody Development Engineer Licensing 40

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody 52

Antibody Licensing Licensing Development 52

Scienmag

SEPTEMBER 9, 2020

Computer design of synthetic proteins is creating potent, stable antivirals that block infection at least as well as monoclonal antibodies Credit: Ian Haydon/UW Medicine Institute for Protein Design Computer-designed small proteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19.

Protein 40

Protein Antibody Medicine Allergies 40

The Pharma Data

DECEMBER 22, 2020

SAITAMA, Japan–( BUSINESS WIRE )– After a capital increase in the initial closing of its series A round, with investments by Mitsubishi UFJ Capital and Real Tech Fund , Epsilon Molecular Engineering Inc. The bio industry has progressed to a point where it deals with proteins from an engineering perspective.

Engineer 52

Engineer Drugs Protein Antibody 52

Advarra

JANUARY 11, 2024

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. One strategy proposed the use of synthetic mRNA or modified mRNA analogs, which can enhance the stability and protein expression of mRNA.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. About NVX-CoV2373.

Protein 52

Protein Vaccination Vaccine Immune Response 52

The Pharma Data

NOVEMBER 2, 2020

2, 2020 — An experimental antibody drug that targets one of the body’s key metabolism regulators may help obese people lose weight — at least briefly. It would take much more research to prove the antibody is safe and effective, Ryan said. Some people given the antibody developed nausea, diarrhea or constipation.

Antibody 52

Antibody Drugs Hormones Insulin 52

BioTech 365

JANUARY 11, 2022

BigHat Biosciences Completes First Stage of Research Collaboration with Amgen BigHat Biosciences Completes First Stage of Research Collaboration with Amgen BigHat’s AI-enabled experimental platform speeds the antibody engineering process to advance design and development of novel protein therapeutics SAN MATEO, … Continue reading →

Research 52

Research Engineer Protein Antibody 52

Pharmaceutical Technology

APRIL 28, 2023

Its scope includes Syngene providing integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development. until 2026. Syngene’s collaboration with Zoetis started in 2011.

Manufacturing 130

Manufacturing Antibody Clinical Supply Protein 130

pharmaphorum

OCTOBER 4, 2022

Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer patients. HER2 is a receptor protein that accelerates cancer cell growth.

FDA Approval 105

FDA Approval Protein Antibody Engineer 105

XTalks

JULY 10, 2023

Rystiggo received FDA approval under the Priority Review designation, specifically for the treatment of gMG in adult patients who have tested positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. The active ingredient in Rystiggo is rozanolixizumab, a humanized IgG4 monoclonal antibody.

FDA Approval 92

FDA Approval Antibody Protein Engineer 92

Pharmaceutical Technology

MARCH 10, 2023

Pharmaceutical and biotechnology industries widely use freeze-drying systems to protect vaccines, antibodies, antibiotics such as penicillin, blood plasma, proteins, enzymes, hormones, viruses, and bacteria from heat and minimise their biological activity.

Manufacturing 147

Manufacturing Production Containment Antibody 147

XTalks

AUGUST 8, 2022

MiroBio is a private biotech company based in the UK that focuses on developing checkpoint agonist antibodies, which are a new class of therapies that work to restore immune balance in patients with autoimmune and inflammatory diseases. MiroBio’s Research Pursuits.

Immune Response 89

Immune Response Antibody Life Science Engineer 89

pharmaphorum

JANUARY 6, 2022

Generate’s machine learning platform is directed at teasing out the three-dimensional structure of human proteins, including how they are folded, to determine function, which is almost impossible to work out simply from an amino acid sequence. Last year, the company made three acquisitions – paying $1.9

Protein 59

Protein Engineer Antibody Drugs 59

XTalks

AUGUST 8, 2024

Antibody-drug conjugates (ADCs) are at the forefront of targeted cancer therapy. They combine the precision of monoclonal antibodies (mAbs) with the potency of cytotoxic drugs to destroy cancer cells, without harming healthy tissue. For the antibody component, the specificity of tumor cells is paramount. “We

Development 64

Development Medicine Antibody Protein 64

Scienmag

APRIL 16, 2021

Dominant G-form Spike protein ‘puts its head up’ more frequently to latch on to receptors, but that makes it more vulnerable to neutralization Credit: Los Alamos National Laboratory. LOS ALAMOS, N.M.,

Antibody 73

Antibody Protein Vaccination Vaccine 73

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Gene Splicing 130

Gene Splicing Gene DNA Recombinant DNA Technology 130

Pharmaceutical Technology

JUNE 4, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Gene 262

Gene Gene Therapy Genetics DNA 262

Pharmaceutical Technology

SEPTEMBER 7, 2022

Biopharma companies are under pressure to do more with less in the production of monoclonal antibody (mAb) therapies. It is a single-stage, single-use chromatographic purification solution designed for use in manufacturing recombinant protein therapeutics. Efficiencies in processes are highly sought. Dr El-Sabbahy: “Yes.

Protein 130

Protein Production DNA Manufacturing 130

The Pharma Data

MAY 27, 2022

Roche today announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from 3-7 June and the European Hematology Association (EHA) 2022 Congress from 9-12 June.

Antibody 52

Antibody In-Vitro Medicine Engineer 52

XTalks

DECEMBER 12, 2023

Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin. Patients have better quality of life thanks to many Grifols plasma-derived medicines that replace missing or deficient plasma proteins.

Medicine 104

Medicine Recombinant Antibody Protein Antibody 104